Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
ZD 2079Cat. No. 2154 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 4-[2-[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethoxy]-benzeneacetic acid hydrochloride |
Biological Activity
β3-adrenoceptor agonist. Relaxes rat mesenteric artery and isolated aorta in vitro. Inhibits ob gene expression and circulating leptin levels in lean mice in vivo.Licensing Information
Sold with the permission of AstraZeneca UK Ltd.Certificate of Analysis / Safety Data Sheet
References
Trayhurn et al (1996) Rapid inhibition of ob gene expression and circulating leptin levels in lean mice by the β3-adrenoceptor agonists BRL 35135A and ZD2079. Biochem.Biophys.Res.Comm. 228 605.
Brawley et al (2000) Role of endothelium/nitric oxide in atypical β-adrenoceptor-mediated relaxation in rat isolated aorta. Eur.J.Pharmacol. 398 285. PMID: 10854841.
Kozlowska et al (2003) Atypical β-adrenoceptors, different from β3-adrenoceptors, relax the rat isolated mesenteric artery. Br.J.Pharmacol. 140 3. PMID: 12967929.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: ZD 2079, supplier, β3-adrenoceptor, b3-adrenoceptor, β3-adrenergic, b3-adrenergic, agonists, Receptors, ZD2079, AstraZeneca
Quick Order
Find multiple products by catalog number
Cardiovascular Guide
Request your free copy
Highlights over 250 products for cardiovascular research. Request a copy or view PDF today.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Regulation of Vascular Reactivity by GPCRs
Written by J.J. Maguire and A.P. Davenport
'Regulation of Vascular Reactivity by G-protein-coupled Receptors' summarizes the key GPCRs regulating vascular reactivity.
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.